Mosnodenvir
Alternative Names: JNJ-1802; JNJ-64281802Latest Information Update: 28 Mar 2025
At a glance
- Originator Janssen Research & Development
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dengue
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Dengue(In volunteers) in Netherlands (PO)
- 04 Oct 2024 Janssen terminates a phase II trial in Dengue (In adolescents, Prevention, In adults) in Brazil, Colombia, Malaysia, Mexico, Panama, Peru, Philippines, Puerto Rico, Thailand (PO) due to strategic reprioritization (NCT05201794)
- 10 Sep 2024 Janssen Research & Development in collaboration with National Institute of Allergy and Infectious Diseases (NIAID) plans a phase-II trial for Dengue (In volunteers) in USA (PO), (NCT05048875)